Category: vitreo-retina
No-assistant technique for glued IOL (7.05 min Video): Dr Priya Narang
| May 19, 2013 | Posted by admin under cataract, IOL, Video, vitreo-retina |
No-assistant technique for glued IOL : Dr Priya Narang MS
An excellent demo video using animation and real surgery videos to explain the tricky concepts in general and the no-assistant technique in particular. (91)
AREDS formula requires tinkering
| May 16, 2013 | Posted by admin under Pharmacology, vitreo-retina |
AREDS formula requires tinkering
Five-year results from the AREDS2 study shows that adding lutein and zeaxanthin, and/or omega-3 fatty acids to the original AREDS formula did not further reduce the risk of AMD progression. However, they found some benefit in two subgroups: Subjects who took an AREDS formulation with lutein and zeaxanthin but no beta-carotene cut their risk by about 18 percent, while those who had very little lutein and zeaxanthin in their diets but took an AREDS formulation with lutein and zeaxanthin were about 25 percent less likely to develop advanced AMD compared with participants with similar dietary intake who did not take lutein and zeaxanthin. The authors recommend a new formula consisting of 400 IU of vitamin E, 500 mg vitamin C, 10 mg lutein and 2 mg zeaxanthin, 80 mg zinc and 2 mg copper.
Journal of the American Medical Association, May 5 2013 (51)
Short-term external buckle shows promise for retinal detachment
| May 8, 2013 | Posted by admin under 2013, Abstract, vitreo-retina |
Short-term external buckle shows promise for retinal detachment
This retrospective case series reports two-year outcomes in 31 patients (33 eyes) with a rhegmatogenous retinal detachment with inferior retinal breaks. The external buckle consisted of a 505 sponge sutured along the blunt side of a 279 tyre. It was deeply embedded into the inferior fornix without suture after pneumatic retinopexy. The buckle remained in place for three days. Twenty-nine eyes achieved successful reattachment within six months with no more treatment. While the procedure failed in four eyes, reattachment was achieved with further treatment.
American Journal of Ophthalmology, April 2013 (62)
Longer axial length may be protective against diabetic retinopathy
| April 26, 2013 | Posted by admin under 2013, Abstract, vitreo-retina |
Longer axial length may be protective against diabetic retinopathy
This literature review evaluated the potential mechanisms, both refractive and structural, by which myopia protects against diabetic retinopathy. Longer axial length was the only variable consistently associated with a lower risk and severity of diabetic retinopathy in patients with myopia. The authors speculate that the decrease in blood flow and/or increase in ocular volume associated with increased axial length may be the mechanism for this protective effect.
Clinical and Experimental Ophthalmology, April 2013 (89)
Beta-blockers may reduce anti-VEGF treatment burden
| April 25, 2013 | Posted by admin under 2013, Abstract, vitreo-retina |
Beta-blockers may reduce anti-VEGF treatment burden
This retrospective case series study included 46 patients with wet AMD treated with bevacizumab injections on a prn regime. Patients treated with systemic beta-adrenergic blocking agents required less intravitreal injections (5.2 vs. 7.9), a statistically significant difference (P= 0.0068, multiple linear regression).
Retina, April 2013 (121)
Intravitreal injections associated with low endophthalmitis rate
| April 23, 2013 | Posted by admin under 2013, Abstract, vitreo-retina |
This retrospective review of all intravitreal injections performed at the Massachusetts Eye and Ear Infirmary over five years shows an endophthalmitis rate of 0.029 percent per injection, three cases out of 10,208 injections. Bacterial cultures revealed coagulase-negative Staphylococcus species, Staphylococcus epidermidis and one negative culture. All cases were successfully treated with either intravitreal antibiotics and steroids or pars plana vitrectomy. Data also suggest that omission of a sterile drape, eyelid speculum or postinjection antibiotics by several of the treating ophthalmologists did not result in an increased rate of postinjection endophthalmitis.
British Journal of Ophthalmology, April 2013 (69)
Prophylactic antibiotics after IVT injection discouraged
| April 22, 2013 | Posted by admin under Abstract, vitreo-retina |
This prospective study evaluated change in antibiotic resistance of ocular surface flora with repeated prophylactic use of antibiotics after intravitreal injection for AMD. The 84 patients in the study group received topical moxifloxacin hydrochloride for three days after each monthly injection. They found that mean minimal inhibitory concentration (MIC) levels increase by 20 percent in the study group compared with a 5 percent decrease among controls. The percentage of resistant isolates and MIC90 were approximately four times higher in the study group than the control group.
Archives of Ophthalmology, April 2013 (98)
Recall of all Clinical Specialties Compounding Pharmacy products
| March 23, 2013 | Posted by admin under news, vitreo-retina |
The FDA has issued an updated alert for an expanded recall of all lots of ALL sterile products repackaged and distributed by Clinical Specialties Compounding Pharmacy (Augusta, Ga.) due to lack of sterility assurance. The recall of all sterile products is conducted in follow-up to concerns regarding practices at the site that cannot assure the sterility of the products. Until further notice, healthcare providers should stop using all sterile products distributed by Clinical Specialties Compounding Pharmacy and return them to the company.
On March 18, Clinical Specialties voluntarily recalled its Avastin (bevacizumab, Genentech, South San Francisco) unit dose syringes. The product has resulted in or potentially could result in an infection within the eye. Clinical Specialties received reports of endophthalmitis infections from physicians’ offices. This product was being used solely in an off-label use by ophthalmologists for macular degeneration and is packaged in sterile syringes distributed to doctors’ offices in Georgia, Louisiana, South Carolina, and Indiana between October 19, 2012 and March 19, 2013.
(Source: EyeWorld Weekly Update) (312)
Recent Comments